How much funding has Avenzo raised?

Avenzo has raised $832.0M in total funding, most recently a Series B round.

Who are Avenzo's investors?

Avenzo's investors include NEA, Deep Track Capital, Sofinnova Investments, Sands Capital, OrbiMed, SR One.

Where is Avenzo headquartered?

Avenzo is headquartered in San Diego, California, United States.

What industry is Avenzo in?

Avenzo operates in Biotech, Oncology, Healthcare.

Avenzo

formerly Avenzo Therapeutics

Developing the next generation of oncology therapies for patients

San Diego, United States · Founded 2022 · $832.0M raised

Biotech

Oncology

Healthcare

Headquarters: San Diego, California
Employees: 1–10
Founded: 2022
Business Model: B2B

Website: avenzotx.com
Total Funding: $832.0M
Last Round: $60.0M Series BSep 2025
Rounds: 4

About

Avenzo Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation small-molecule and antibody-drug conjugate (ADC) therapies for oncology. Founded in 2022 by veterans of Turning Point Therapeutics (acquired by Bristol Myers Squibb for $4.1B in 2022), the San Diego-based company targets cancers with high unmet medical needs. The company has raised over $60M in Series B financing with backing from OrbiMed, Foresite Capital, SR One, NEA, Lilly Asia Ventures, Sands Capital, and others.

Summary

Avenzo is a Biotech company based in San Diego, United States, founded in 2022. It has raised $832.0M in total across 4 rounds, most recently a $60.0M Series B round in Sep 2025. Investors include NEA, Deep Track Capital and Sofinnova Investments.